Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants

Company Overview - Genelux Corporation is a late clinical-stage immuno-oncology company focused on developing next-generation oncolytic immunotherapies for aggressive and difficult-to-treat solid tumors [5] - The company's leading product candidate, Olvi-Vec, is a modified strain of the vaccinia virus currently undergoing a Phase 3 trial for platinum-resistant/refractory ovarian cancer [5] Public Offering Details - Genelux has initiated an underwritten public offering of its common stock and accompanying warrants, with the expectation to grant underwriters a 30-day option to purchase an additional 15% of the shares sold [1][2] - Guggenheim Securities is the sole book-running manager, while Newbridge Securities Corporation acts as co-manager for the offering [2] Regulatory Compliance - The shares are being offered under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC), and the offering will be conducted via a written prospectus [3]